CD5基因签名识别了对布鲁顿的氨酸激酶抑制敏感的扩散大B细胞淋巴瘤
Alan Cooper1, Sravya Tumuluru2, Kyle Kissick3
1Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
概括
一种新的CD5基因表达特征 (CD5sig) 识别了可能受益于布鲁顿氨酸激酶抑制剂 (BTKi) 治疗的扩散性大B细胞淋巴瘤 (DLBCL) 患者,补充了现有的治疗选择方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 的治疗反应有所不同.
- 目前的基因分类器如LymphGen在临床应用和捕获所有响应的DLBCL亚型方面存在局限性.
- 布鲁顿的氨酸激酶抑制剂 (BTKis) 在治疗某些DLBCL中表现有前途.
研究的目的:
- 开发一种新的CD5基因表达特征 (CD5sig) 作为预测DLBCL中BTKi治疗反应的生物标志物.
- 评估CD5sig在识别受益于BTKi治疗的DLBCL中的实用性,独立于现有的分类.
主要方法:
- 在404个DLBCL中进行了CD5免疫组织化学 (IHC).
- 基于CD5 IHC+和CD5 IHC-非生殖中心B细胞样 (非GCB) DLBCL之间的差异基因表达,构建了一个60基因的CD5sig.
- 在外部数据集上验证了CD5sig,包括PHOENIX研究队列 (n=584),以评估其预测对ibrutinib加R-CHOP治疗反应的能力.
主要成果:
- 在12%的非GCB DLBCL中发现了CD5表达,与B细胞受体 (BCR) 激活相关.
- CD5sig成功地在多个数据集中识别了DLBCLs,这些DLBCL具有BCR依赖的遗传和非遗传基础.
- 在PHOENIX研究中,CD5sig+DLBCLs在ibrutinib加R-CHOP的治疗中显示出生存优势,不论是淋巴基因分类.
结论:
- CD5sig作为一种有价值的生物标志物,用于识别对基于BTKi的疗法敏感的DLBCL.
- CD5sig补充了现有的生物标志物,通过识别更广泛的DLBCLs,可以从BTKi处理中受益.
- 这种特征有助于完善DLBCL患者的治疗策略.
相关概念视频
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...